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Canine alphacoronaviruses (CCoV) exist in two serotypes, type I and II, both of which can cause severe
gastroenteritis. Here, we characterize a canine alphacoronavirus, designated CCoV-A76, ﬁrst isolated in
1976. Serological studies show that CCoV-A76 is distinct from other CCoVs, such as the prototype CCoV-
1-71. Efﬁcient replication of CCoV-A76 is restricted to canine cell lines, in contrast to the prototypical
type II strain CCoV-1-71 that more efﬁciently replicates in feline cells. CCoV-A76 can use canine
aminopeptidase N (cAPN) receptor for infection of cells, but was unable to use feline APN (fAPN). In
contrast, CCoV-1-71 can utilize both. Genomic analysis shows that CCoV-A76 possesses a distinct spike,
which is the result of a recombination between type I and type II CCoV, that occurred between the
N- and C-terminal domains (NTD and C-domain) of the S1 subunit. These data suggest that CCoV-A76
represents a recombinant coronavirus form, with distinct host cell tropism.
& 2012 Elsevier Inc. All rights reserved.Introduction
Coronaviruses are single-stranded RNA viruses which infect
humans and a variety of non-primate mammals, including canines
(Lai and Holmes, 2001; Perlman et al., 2008). Research on these
viruses has greatly increased since 2003 due to the severe acute
respiratory syndrome (SARS) pandemic caused by a zoonotic
transmission of an animal coronavirus into the human population
(Eaton and Wang, 2007). Coronaviruses are phylogenetically
divided into several genera termed alpha, beta, gamma and delta
(King et al., 2011). There are two known coronavirus species that
infect dogs: a newly identiﬁed betacoronavirus termed canine
respiratory coronavirus (CRCoV), and a more characterized alpha-
coronavirus termed canine enteric coronavirus (CCoV) (Decaro and
Buonavoglia, 2008). Within the CCoV alphacoronavirus species,
there are two distinct serotypes (type I and type II), with both
forms of CCoV transmitted via a fecal–oral route (Decaro and
Buonavoglia, 2008). CCoV is usually thought to cause only mild to
inapparent enteritis (Pollock and Carmichael, 1983). However, in
some cases CCoV infection can be fatal in young dogs, in particular
when coinfections occur with canine parvovirus or other pathogensll rights reserved.
r).
.(Pratelli et al., 1999). In recent years, an increasing number of
highly virulent CCoV infections have also been reported in healthy
adult dogs without apparent coinfections (Buonavoglia et al., 2006;
Decaro et al., 2007; Escutenaire et al., 2007; Evermann et al., 2005;
Naylor et al., 2002; Sanchez-Morgado et al., 2004; Zappulli et al.,
2008). In some of these cases, these new pathogenic viruses are able
to spread to other organs and are thought to be novel recombinant
forms of CCoV, such as the CCoV type IIb viruses that are more
closely related to transmissible gastroenteritis virus (TGEV) of pigs
(Decaro and Buonavoglia, 2008; Decaro et al., 2009; Erles and
Brownlie, 2009; Ntaﬁs et al., 2011). The emergence of such highly
virulent isolates of CCoV has signiﬁcantly renewed interest in this
group of viruses.
CCoV particles are composed of four major structural proteins
termed spike (S), envelope (E), membrane (M) and nucleocapsid
(N) (Hogue and Machamer, 2008). CCoV type I and CCoV type II
are closely related to each other except for markedly different
spike proteins and the presence of an additional open reading
frame (ORF3) in CCoV type I isolates (Lorusso et al., 2008). This is
analogous to the situation with feline coronavirus (FCoV), which
also exist as two serotypes (type I FCoV and type II FCoV) based
on distinct spike proteins (Haijema, et al., 2007). It has been
proposed that type I CCoVs and FCoVs evolved from a common
ancestral virus, and that the canine and feline type II lineages
arose from multiple recombination events with an unidentiﬁed
genetic source (Lorusso et al., 2008). Also closely related to the
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which may have arisen from zoonotic transfer of a type II CCoV to
pigs (Lorusso et al., 2008).
The coronavirus spike protein is a major antigenic determinant
and is also responsible for host cell receptor binding and viral
entry (Gallagher and Buchmeier, 2001). Aminopeptidase N (APN)
has been shown to act as a cellular receptor for FCoV, CCoV and
TGEV (Wentworth and Holmes, 2001). Although each virus would
be assumed to utilize a species-speciﬁc homolog in its respective
host during in vivo infection, the feline homolog (fAPN) can act,
in vitro, as a common receptor for type II FCoV, type II CCoV and
TGEV(Tresnan et al., 1996). This situation is unlike the one found
for most other coronaviruses, which have highly species-speciﬁc
receptors. This broad receptor binding ability likely plays a role in
the zoonotic transfer and genetic recombination events that have
deﬁned the evolution of animal alphacoronaviruses. In the case of
the serotype I FCoV/CCoV group, the receptor determinants are
much less certain. While there is some evidence for fAPN as an
FCoV type I receptor (Tresnan et al., 1996), other studies have
concluded that there is a distinct receptor for FCoV type I (Dye
et al., 2007; Hohdatsu et al., 1998). Receptor determinants for
CCoV type I remain essentially unknown. In addition to a speciﬁc
proteinaceous receptor, there are indications that lectin-based
interactions via sugar moieties, on either the virus or the host,
may play a role in the receptor-binding complex for FCoV types I
and II and TGEV (Krempl et al., 1997; Regan et al., 2010; Regan
and Whittaker, 2008; Schultze et al., 1996; Van Hamme et al.,
2011).
Most CCoVs isolated to date are type II viruses. These are easily
cultivated in vitro (Pollock and Carmichael, 1983), with canine
A-72 cells typically used for virus isolation. In contrast, type I
CCoVs have yet to be easily cultivated in cell culture, and were
only recently discovered by reverse-transcription polymerase
chain reaction from canine fecal RNA (Pratelli et al., 2003).
CCoV-A76 was isolated from a closed breeding colony of Beagles
at the James A. Baker Institute for Animal Health (Cornell
University, Ithaca, NY) in 1976. The dogs presented primarily
with enteritis, but the virus also appeared to cause additional
clinical signs, with signiﬁcant morbidity in litters of newborn
pups exposed to the virus, and with abortions in some pregnant
bitches (Carmichael, 1978). The virus was readily isolated, and
was later noted to possess distinct antigenic characteristics
as compared to other type II CCoV isolates (Corapi et al., 1992).
CCoV-A76 was archived at the Animal Health Diagnostic Center
(College of Veterinary Medicine, Cornell University, Ithaca, NY)
and further characterization was not performed. In light of recent
interest in CCoV, we obtained this specimen from the archive forFig. 1. In vitro growth and antigenic identiﬁcation of CCoV-A76. A-72 cells were inocul
quantiﬁed 48 h p.i. for CCoV-A76 and other closely related alphacoronaviruses (A). A
coronavirus N monoclonal antibody (mAb) FIPV3-70 (B).further study. Here, we report data on in vitro growth, antigenic
and genomic analysis of CCoV-A76, and show that it represents a
recombinant CCoV.Results
In vitro cultivation of CCoV-A76
A previous study indicated CCoV-A76 to be antigenically
distinct from other CCoV isolates (Corapi et al., 1992), however
further characterization was not reported. To perform more
extensive analysis, we obtained samples of CCoV-A76 from the
Animal Health Diagnostic Center (Cornell University, Ithaca, NY)
and inoculated a canine cell line (A-72). Supernatant and cells
were tested for viral titer by plaque assay on A-72 cells, demon-
strating that CCoV-A76 infection produces large quantities of
extracellular particles (Fig. 1A). This is similar to results observed
with other viruses such as type II CCoV-1-71, type II FCoV-1146,
and TGEV-Purdue, but different than virus isolates such as type I
FCoV-TN406 (FIPV-Black), which exclusively produce cell-asso-
ciated virions (Fig. 1A). The identiﬁcation of A76 as a coronavirus
was conﬁrmed by immunoﬂuorescence microscopy using the
antibody FIPV3-70, a generally cross-reactive CoV nucleocapsid-
speciﬁc monoclonal antibody (Fig. 1B).Antigenic analysis of CCoV-A76
The antigenic characteristics of CCoV-A76, along with other
alphacoronaviruses, were further analyzed by immunoﬂuorescence
microscopy using polyclonal anti-CCoV sera, with mAb FIPV3-70,
and with a panel of monoclonal antibodies previously tested against
CCoV-A76 (anti-nucleocapsid (N): 16C11.13, 17B7.1; anti-spike (S):
18A7.4, 18H9.1, 19G11.10, 21D10.2, 22G6.4, 23A1.8) (Corapi et al.,
1992) (Fig. 2A and B). The CCoV type II isolates CCoV-1-71, CCoV-
S378, CCoV-K378, the FCoV type II isolates FCoV-1146, FCoV-1683,
FCoV-DF2, the FCoV type I isolate FCoV-TN406 (FIPV-Black), and
TGEV-Purdue were all antigenically analyzed for comparison. The
distantly related betacoronavirus MHV-A59 was also tested as an
outlier control. The polyclonal anti-CCoV sera and all three anti-
nucleocapsid mAbs reacted strongly with all alphacoronavirus
isolates tested including CCoV-A76, but did not react with MHV-
A59 (Fig. 2B). All six anti-spike mAbs reacted with FCoV-1146,
FCoV-1683, FCoV-DF2 (Fig. 2B). Four of the six anti-spike mAbs
(18A7.4, 19G11.10, 22G6.4, 23A1.8) reacted with the CCoV type II
isolates CCoV-1-71, CCoV-S378, CCoV-K378 and TGEV-Purdueated with CCoV-A76 and extracellular virus (EV) or cell-associated virus (CAV) was
-72 cells were infected with CCoV-A76 and stained 12 hours p.i. with the anti-
Fig. 2. Antigenic analysis of CCoV-A76. CCoV-A76 and CCoV-1-71 infected cells were stained by immunoﬂuorescent microscopy with the anti-FCoV nucleocapsid mAb
16C11.13 and the anti-FCoV spike mAb 18A7.4 (A). Cells were infected with an assortment of closely related alphacoronaviruses or MHV and stained with either anti-CCoV
antisera, the anti-FCoV nucleocapsid mAbs FIPV3-70, 16C11.13 and 17B7.1, or the anti-FCoV spike mAb 18A7.4, 18H9.1, 19G11.10, 21D10.2, 22G6.4, or 23A1.8 (B). (þ)
represents a positive reaction, () represents a negative reaction.
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CCoV-A76 (Fig. 2B).
Cell tropism of CCoV-A76
To further characterize the in vitro growth characteristics of
CCoV-A76, multiple cell lines including canine (A-72, MDCK, Cf2Th,
CDKE-2), feline (CRFK, AK-D, Fc2Lu, FMEC), porcine (LLC-PK1), and
murine (NIH-3T3) were inoculated with CCoV-A76 at an MOI of 1
(Fig. 3A and B). All cell lines were also inoculated with closely
related CCoV type II isolates (CCoV-1-71, CCoV-S378, CCoV-K378),
FCoV type II isolates (FCoV-1146, FCoV-1683, FCoV-DF2), FCoV
type I isolate (FCoV-TN406), and TGEV-Purdue. The CCoV type II
isolates CCoV-1-71, CCoV-S378 and CCoV-K378 infected all feline
cell lines tested, but did not infect any canine or porcine cell lines,
except A-72 cells at a low efﬁciency (30, 27 and 22% respectively)
(Fig. 3B). The FCoV type II isolates FCoV-1146, FCoV-1683 and
FCoV-DF2 also efﬁciently infected all feline cell lines and A-72 cells,
but not other canine or porcine cell lines tested (Fig. 3B). The FCoV
type I isolate FIPV-TN406 infected the feline cell line AK-D only
(Fig. 3B). TGEV-Purdue efﬁciently infected the porcine LLC-PK1
cells, and also infected all feline cell lines and A-72 cells at overall
reduced efﬁciency. CCoV-A76 efﬁciently infected all canine cell
lines tested, but was unable to infect any feline cell lines. CCoV-A76infected LLC-PK1 cells at a reduced efﬁciency (24%). None of the
viruses tested infected the murine NIH-3T3 cell line (Fig. 3B).
Use of canine and feline APN as a CCoV-A76 receptor
Because of the distinct tropism for CCoV-A76 for canine vs.
feline cells, we examined the utilization of canine vs. feline APN
as a CCoV-A76 receptor (Fig. 4). Non-permissive BHK cells were
transfected to express either fAPN or cAPN, and infected with
CCoV-A76, along with CCoV-1-71 and FCoV-1683 as controls.
CCoV-A76 was able to infect BHK cells expressing cAPN, but was
unable to infect cells expressing fAPN (Fig. 4A). In contrast, both
CCoV-1-71 and FCoV-1683 were able to infect cells expressing
either cAPN or fAPN (Fig. 4B and C).
Sequencing and phylogenetic analysis of CCoV-A76 genome
Viral RNA was puriﬁed from CCoV-A76 particles and subjected
to genome sequencing (C Town, unpublished results). Most
viral ORFs were successfully sequenced and annotated, with the
exception of ORF1ab, where only the 30 end of ORF1ab sequence
has been obtained. In general, the sequences for all non-structural
and structural proteins, except for the spike, were more related to
type II CCoV than to type I (Supplementary Fig. 1), suggesting that
Fig. 3. Cell tropism of CCoV-A76. Canine MDCK cells were infected with either CCoV-A76 or CCoV-1-71 and stained for immunoﬂuorescence microscopy with the anti-
coronavirus N mAb FIPV3-70 (A). A variety of cells lines were tested for their susceptibility to CCoV-A76 and a number of closely related coronavirus isolates (B). Results
are expressed as percent infected cells as determined by immunoﬂuorescence assay. The mammalian species of each cell line used, Canis familiaris (dog), Sus scrofa (pig),
Felis catus (cat), and Mus musculus (mouse) are speciﬁed on top of cell line names. 4500 cells were quantiﬁed from each of three independent experiments. Error bars
represent standard deviation of the means.
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Intriguingly, this analysis has shown that the S protein has a
sequence that would correspond to an intermediate between pro-
totypical type I and type II CCoVs (CCoV-Elmo/02 and CCoV-1-71
respectively, Supplementary Fig. 1).
Phlyogenetic analysis of CCoV-A76 spike
Because the CCoV-A76 spike sequence did not cluster well
with either type I or II CCoVs, and since the spike protein is a
determinant of cell tropism and viral pathogenesis, we focused on
the spike protein sequence to perform a more extensive phylo-
genetic analysis (Fig. 5). Overall, the complete spike protein was
distinct from other alphacoronaviruses and did not cluster with
either type I or type II CCoVs (Fig. 5A). Analysis of the S2 (fusion)
domain showed that it clustered closely with CCoV type II, FCoV
type II and TGEV (Fig. 5B). In contrast, the S1 (receptor binding)
domain clustered with type I CCoV (Elmo/02) and type I FCoV
(RM) (Fig. 5C). Notably, the CCoV-A76 spike sequence lacked a
putative furin cleavage site (RRARR) previously shown to be
present at the S1/S2 junction of the CCoV type I virus Elmo/02
(de Haan et al., 2008; Pratelli et al., 2003), indicating it was more
similar to CCoV type II viruses that do not contain consensus furin
cleavage sites (Supplementary Fig. 2). Coronavirus S1 domains
contain two independent functional sub-domains, the N-terminal
domain (NTD) and the C-terminal domain (C-domain) (Peng et al.,
2011). To better characterize CCoV-A76 S1, the NTD and
C-domain were independently analyzed by phylogenetic analysis.
The CCoV-A76 NTD clustered closely with Elmo/02 and did notcluster with 1–71 (Fig. 5D). In contrast, the CCoV-A76 C-domain
was divergent and did not clearly cluster with any characterized
alphacoronavirus (Fig. 5E). Overall, these data indicate that the
CCoV-A76 spike gene is probably a recombinant of a type I CCoV
with a type II CCoV spike, with a recombination site located
between the NTD and C-domain of S1. To determine possible
recombination sites within S1, we used the BOOTSCAN/RESCAN
method to identify recombination events and breakpoints in the
CCoV-A76 S nucleotide sequence. This analysis conﬁrmed the
presence of recombination between the NTD and C-domain, with
a breakpoint at nucleotide 890 (Fig. 6).Discussion
In a survey of canine coronaviruses stored at Cornell Univer-
sity, we carried out a retrospective analysis of a CCoV ﬁrst isolated
in 1976 (CCoV-A76), which has previously been shown to be
antigenically distinct from typical type II CCoVs (Corapi et al.,
1992). Immunoﬂuorescence experiments have shown that a panel
of antibodies speciﬁc for the coronavirus N protein cross reacts
with CCoV-A76, but a panel of antibodies speciﬁc for the type II
FCoV S protein fails to cross react with the virus. Importantly,
while both CCoV-A76 and CCoV-1-71-like viruses can infect
canine A-72 cells, CCoV-A76 shows distinct and pronounced
tropism for a variety of additional dog cell lines (e.g. MDCK), as
well as pig cell lines (e.g. LLC-PK1) that the prototypical 1–71-like
CCoVs fail to infect. Additionally, CCoV-A76 fails to infect cells of
cat origin (e.g. CRFK, AK-D), which are very efﬁciently infected by
Fig. 4. Canine APN, but not feline APN, as a functional receptor for CCoV-A76. Non-permissive BHK-21 cells were transfected with 400 ng of plasmids encoding
FLAG-canine-APN (cAPN), feline-APN (fAPN) or mock transfected for 18 h. The transfected cells were then infected at an MOI of 1–5 with CCoV-A76 (A), CCoV-1-71 (B),
FCoV-1683 (C) or mock infected (D) for 8 h. Cells were stained for immunoﬂuorescence microscopy analysis with anti-coronavirus N mAb FIPV3-70 for infection and with
RG4 and anti-FLAG-M2 antibodies for feline APN and canine APN expression, respectively.
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possesses distinct characteristics setting it apart from other
known CCoVs. Phylogenetic analysis of the CCoV-A76 genome
shows that it is mostly related to type II CCoV, however, analysis
of the spike sequence at the amino acid level places CCoV-A76 as
an outlier of the CCoV group, suggesting that CCoV-A76 is
genetically distinct. Notably, CCoV-A76 is genetically distinct
from recently isolated highly virulent type IIb CCoV strains, such
as CCoV-CB/05. CCoV-A76 S appears to be a recombinant of a
type II and a type IIa CCoV, with recombination occurring
between the NTD and C-domain of S1 (Fig. 7). Further proof of a
recombination event occurring at the spike gene of CCoV-A76 was
found by analyzing its nucleotide coding sequence. Indeed, in
close proximity of the recombination breakpoint identiﬁed by the
BOOTSCAN/RESCAN methodology (nucleotide 890), several
stretches of nucleotides that were either identical (TCTAA, found
twice at nucleotide 932 and at nucleotide 972) or near identical
(ATAAAAAT at nucleotide 862 and GTAAAATG at nucleotide
990) to characterized CCoV recombination signals (TCTAA and
G/CTAAAAA/GT) (Wang and Lu, 2009) have been identiﬁed (data
not shown). The divergent C-domain might also suggest that
a second recombination may have occurred at the vicinity of the
S1/S2 boundary, with an as yet uncharacterized coronavirus, but
evidence for this is currently lacking. Overall, the body of
evidence in favor of a recombinant origin for the spike gene of
CCoV-A76, together with its distinct antigenic and tropism
proﬁles, argue in favor of setting it apart from other CCoVs as a
type I/II canine coronavirus.While it is clear that CCoV-A76 has a much more highly
species-speciﬁc receptor-binding pattern compared to typical
type II CCoVs (e.g. CCoV-1-71), or to typical type II FCoVs (e.g.
FCoV-1683), the reasons behind this are less clear. The APN-
binding site is within the C-domain of S1 and can be operationally
deﬁned as the D3 domain (residues 526–676, based on TGEV
nomenclature (Reguera et al., 2011)). However, individual amino
acids within the D3 domain that might confer strict species
speciﬁcity have not been identiﬁed. BLAST analysis based on
the amino acid sequence of CCoV-A76 D3 domain shows that
it is most similar to type II CCoV, but is clearly divergent
(Supplementary Fig. 3). It also shows some similarity to porcine
coronaviruses, perhaps accounting for the limited tropism seen for
porcine cells. The divergent C-domain may impart more strict
species speciﬁcity to CCoV-A76, via speciﬁc interactions within the
D3 domain. It is also possible that an interaction between the APN
binding site and the distinct CCoV type I-like NTD found in CCoV-
A76 might account for the distinct species speciﬁcity of this virus.
Overall, while CCoV-A76 clearly has a recombinant origin, it should
be remembered that the recombination event has not occurred
within the known APN-binding domain (D3 domain, residues 526–
676), but between the NTD and the C-domain (around residue 297,
Fig. 7). As such, the recombination event itself is unlikely to be
directly responsible for the distinct receptor-binding characteristics
of CCoV-A76, which may be caused by D3 domain divergence
through missense mutations or via the inﬂuence of the distinct NTD.
In the case of APN itself, previous studies have shown that
molecular determinants of species speciﬁcity lie in glycosylation
Fig. 5. Phylogenetic analysis of CCoV-A76 spike. The phylogenetic analysis was performed using full-length coronavirus spike amino acid sequences (A), the S2 subunit
sequences including the transmembrane (TM) and C-termini (CT) (B), the S1 subunit sequences (C), the S1 N-terminal domain (NTD) sequences (D), and the S1 C-terminal
domain (C-domain) sequences (E). The sequences used in the analyses are represented for each tree, with the region of spike that is used shown in black, and the region not
included shown in gray. The S1/S2 cleavage site of the coronavirus spike protein was used as the delineating site between S1 and S2 domains. Determination of NTD and
C-domain of the CoV S1 used in the analysis was performed by alignment of individual spikes with MHV-A59 sequence, which has deﬁned NTD and C-domain sequences.
The trees were generated using ClustalX 2.1 with the Neighbor-Joining method and bootstrap values calculated from 2000 trees. Scale bars represent the estimated
number of substitutions per site.
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glycan prediction software reveals that cAPN is more extensively
glycosylated than fAPN (with cAPN having 5 potential glycosyla-
tion sites on the solvent exposed domain while fAPN has only 2).
In particular, residues 291–293 were shown to control species
speciﬁcity between human, porcine and feline APN (Wentworth
and Holmes, 2001). However, this glycosylation sequon is absent
for both fAPN and cAPN. Analysis of the spike-interacting APNdomain previously shown to control species speciﬁcity (residues
670–840) (Hegyi and Kolb, 1998) reveals the presence of a
glycosylation site sequon NTS for cAPN, which is missing in fAPN
(Supplementary Fig. 4). As with hAPN (Wentworth and Holmes,
2001), this sequon may control the species speciﬁcity of APN.
However, the effect of this glyscosylation site in the context of
infection by CCoV-A76 remains to be tested experimentally.
While fAPN has been considered to be a universal receptor for
Fig. 6. BOOTSCAN/RESCAN recombination analysis of CCoV-A76 spike. The full-length nucleotide sequences of CCoV-A76, CCoV-1-71, and CCoV-Elmo/02 spike genes were
used to perform a recombination event analysis using the RDP3 software with the BOOTSCAN/RESCAN method. The program detected a possible recombination event
between the parental sequences CCoV-1-71 S and CCoV-Elmo/02 S that led to the formation of CCoV-A76 spike. The BOOTSCAN plot display shows the location of the
probable recombination event in the alignment, with a breakpoint detected at nucleotide 890 (corresponding to residue 297) of CCoV-A76 S.
Fig. 7. Schematic of evolutionary origins of the CCoV-A76 spike. The schematic displays the origins of the different domains and subdomains of CCoV-A76 spike as well as
the major recombination event that was found by phylogenetic relationship and BOOTSCAN/RESCAN analyses. NTD: N-terminal domain of S1; C-domain: C-terminal
domain of S1; D3: receptor binding domain (residues 526–676, in blue highlight); TM: trans-membrane domain. Not drawn to scale.
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uses ACE-2 as a receptor), the situation for the type I FCoV/CCoV
lineage is less clear, with the usage of an fAPN receptor much
less certain. Our data clearly indicate that CCoV-A76 is another
exception to the idea that fAPN is a universal receptor within the
alphacoronavirus subfamily.
Coronaviruses are known to efﬁciently recombine, especially
within the spike gene, to modulate host range and pathogenesis
(Graham and Baric, 2010). This has been most well demonstrated
with the type II FCoVs, which have clearly been shown to
represent a recombinant between a type I FCoV and a type II
CCoV (Herrewegh et al., 1998; Vennema et al., 1998) and represent
a replacement of the entire spike gene. In dogs, both type I and
type II CCoVs are circulating extensively and a molecular analysis
of fecal samples has revealed the simultaneous presence of CCoV
type I and CCoV type II in 38/177 naturally-infected dogs (Decaro
et al., 2005). Thus, a likely scenario for the emergence of CCoV-A76
is that CCoV type I and CCoV type II were both circulating in the
animal breeding facilities at Cornell University in 1976, with dogs
infected simultaneously with both serotypes allowing for recom-
bination between the two distinct spike genes. In this scenario, it
is interesting to note that a CCoV type I virus would have been
circulating in the dog population long before the identiﬁcation of
the prototype CCoV type I strain Elmo/02 in 2002.
It remains unclear whether highly virulent A76-like viruses are
naturally circulating in dogs, or if CCoV-A76 represents a deﬁned
recombination event, possibly with limited dog–dog transmis-
sion. Whereas most of the prototype or newly described patho-
genic CCoVs have been ascribed to the CCoV type I family (e.g.
CCoV-Elmo/02), the CCoV type IIa family (e.g. CCoV-1-71) or the
CCoV type IIb family (e.g. CCoV-CB/05), a number of outbreaks of
highly virulent coronavirus infection remain incompletely char-
acterized at a molecular level. Of particular interest is a series ofCCoV outbreaks of gastroenteritis in Sweden (Escutenaire et al.,
2007). Four closely related CCoVs were identiﬁed, typiﬁed by the
strain CCoV-Uppsala2/04. While only limited genomic analysis of
these viruses was performed, it is apparent that the Uppsala2/04-
like CCoVs contained an S protein with N-terminal and C-terminal
domains closely related to CCoV type I and type II respectively—
also indicating their possible origin from recombination between
the two CCoV genotypes.
Our data provide further support for the modular nature of the
coronavirus spike glycoprotein. With this in mind, it will be
important to examine any outbreaks of highly virulent corona-
virus infection of dogs in the context of novel recombinants
between CCoV type I and type II and to consider novel recombi-
nants between the S1 NTD and C-domain as possible zoonotic
coronaviruses.Material and methods
Cell lines
Crandell-Rees feline kidney (CRFK), feline lung (AK-D), Madin-
Darby canine kidney (MDCK), porcine kidney (LLC-PK1) and rat
lung (L2) cells were obtained from the American Type Culture
Collection (ATCC). Canine thymus (Cf2Th), canine kidney (CDKE-2),
and feline lung (Fc2Lu) cells were obtained from the Cornell
Animal Health Diagnostic Center (Cornell University, Ithaca, NY).
Canine ﬁbroblast (A-72) cells were obtained from Dr. Colin Parrish,
Baker Institute for Animal Health (Cornell University, Ithaca, NY).
Polarized feline mammary epithelial cells (FMEC) were obtained
from Dr. John Parker, Baker Institute for Animal Health (Cornell
University, Ithaca, NY). Murine NIH-3T3 cells were obtained from
Dr. Richard Cerione, College of Veterinary Medicine, Department of
A.D. Regan et al. / Virology 430 (2012) 90–99 97Molecular Medicine (Cornell University, Ithaca, NY). All cells were
grown at 371C with an atmosphere of 5% CO2, in RPMI-1640
supplemented with 10% fetal bovine serum (FBS), 10 mM gluta-
mine, 100 U/mL penicillin and 10 mg/mL streptomycin.
Antibodies
The mouse monoclonal anti-coronavirus antibody FIPV3-70
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Feline polyclonal anti-CCoV antisera and anti-feline FITC was
obtained from Veterinary Medical Research and Development
Inc. (Pullman, WA). Mouse monoclonal anti-FCoV nucleocapsid
antibodies 16C11.13 and 17B7.1, and mouse monoclonal anti-
FCoV spike antibodies 18A7.4, 18H9.1, 19G11.10, 21D10.2,
22G6.4, and 23A1.8 were obtained from the Cornell Animal
Health Diagnostic Center (Cornell University, Ithaca, NY). Mouse
monoclonal anti-FLAG-M2 was bought from Sigma Aldrich and
mouse monoclonal anti-fAPN (RG4) was provided by (Hohdatsu
et al. (1998).
Viruses
CCoV-A76 (also referred to as CCoV-A76/5), CCoV-1-71, CCoV-
K378 (CCoV-K378/6), CCoV-S378 (CCoV-S378/3), FCoV-1683
(FECV WSU 79-1683), FCoV-DF2 (FIPV-DF2), FCoV-TN406 (FIPV-
Black) and TGEV-Purdue were obtained from the Cornell Animal
Health Diagnostic Center (Cornell University, Ithaca, NY). FCoV-
1146 (FIPV WSU 79-1146) and mouse hepatitis virus strain A59
(MHV-A59) were obtained from the ATCC. CCoV-A76 was grown
in A-72 cells. CCoV-1-71, CCoV-K378 and CCoV-S378 were grown
in CRFK cells. FCoV-1683, FCoV-DF2 and FCoV-TN406 were grown
in AK-D cells or A-72 cells. TGEV-Purdue was grown in swine
testicle (ST) cells. MHV-A59 was grown in L2 cells. All viruses
(except FCoV-TN406) were grown by inoculating cells at an MOI
of 0.1 and harvesting supernatant after CPE was observed
in 480% of cells (typically between 36 and 48 h). Supernatant
was then cleared of cellular debris with a low-speed spin at
2500 rpm for 15 min and then stored at 801C. FCoV-TN406 was
inoculated at an MOI of 1 and harvested after 48 h by scraping
cells into the media, passaging the mixture 5 times through a 25-
gauge needle, and storing at 801C.
Virus growth and infection assays
Viral infections were carried out by inoculating cells at the
speciﬁed MOI in media as previously described except without
FBS. Cells were then incubated for 60 min at 371C with gentle
rocking to allow viral adsorption. After binding, cells were washed
twice with phosphate buffered saline (PBS) and replaced with
standard media supplemented with 2% FBS and allowed to
incubate for the speciﬁed amount of time. For growth assays,
either supernatant or cells were collected and processed as
described above. Plaque assays were carried out by standard
methods. For infection assays, cells were ﬁxed at either 24 h post-
infection (p.i.) for FCoV-TN406, or 12 h p.i. for all other viruses.
Cells were processed for immunoﬂuorescence microscopy as
previously described (Regan et al., 2008).
Microscopy
Differential interference contrast (DIC) images were generated
on a Zeiss Axiovert 200 inverted microscope. Immunﬂuorescence
images were generated on a Nikon Eclipse E600 ﬂuorescence
microscope. All images were captured on a Sensicam EM camera
(PCO, Kelheim, Germany) and processed with IPLab software
(BioVision Technologies, Exton, PA).Cloning and expression of canine aminopeptidase N (cAPN)
Total RNA was extracted from A-72 cells using an RNeasy
Plus Mini Kit (Qiagen). cDNA was ampliﬁed by the OneStep
RT-PCR kit (Qiagen) and the desired band of molecular weight
3 kb was excised by gel puriﬁcation and cloned into pTOPO
using a TOPO TA cloning kit (Invitrogen). In order to detect
cAPN efﬁciently, a construct, pCMV-tag1-FLAG-cAPN (with a
N-terminal FLAG tag) was created for expression in mammalian
cells. The tag was added by cloning cAPN sequence into
the pCMV-tag1 vector (Agilent). The construct was sequence
conﬁrmed by the Cornell University Life Sciences Core Labora-
tories Center (CLC). Expression was veriﬁed by immunoﬂuores-
cence microscopy using the mouse monoclonal anti-FLAG-M2
antibodies.
RNA sequencing
Viral RNA was extracted using the QIAamp Viral RNA Mini Kit
(QIAGEN). Puriﬁed genomic RNA was reverse transcribed in an
oligo-dT-primed reaction using SuperScript III (Invitrogen).
Amplicons covering most of the 30 one third of the genome were
generated by PCR using Accuprime (Invitrogen) and the following
primer sets: A765-1B-Fwd GCTGCTCTTTACAGAGCGTAT and
A765-S2-Rev GTAACTGGTTACAACGAGGAT; A765-S2-Fwd GGCG-
TTTGTGACAATGGAGCA and A765-7b-Rev ACGTGCTTACCATTCTG-
TACA. These generated two amplicons of 6 kb each with an
overlap of 500 bp. Amplicons were gel puriﬁed and pooled in
equimolar amounts after which they were simultaneously
ampliﬁed and bar-coded in two separate reactions using SISPA
(http://www.biomedcentral.com/1471-2164/9/5). A pool of these
and other viral samples were used to construct 454 and Illumina
libraries and sequenced on their respective platforms. After
sequencing, reads from each platform were deconvoluted by bar
code and trimmed for quality and to remove the SISPA hexamer
primer sequences. Both GS-FLX and Illumina reads were then de
novo assembled using CLC Bio’s clc_novo_assemble program. The
ﬁnal sequence assembly was annotated using the VIGOR pipeline
(http://www.biomedcentral.com/1471-2105/11/451).
CCoV-A76 nucleotide and protein sequences accession numbers
The nucleotide sequences of the CCoV-A76 ORF1ab (partial
sequence), spike (S), 3a, 3c, envelope (E), membrane (M), nucleocap-
sid (N), 7a and 7b genes have been deposited in the National Center
for Biotechnology Information (NCBI) GenBank database under the
following accession number—GenBank ID: JN856008.1. The accession
numbers for the individual NCBI GenBank protein sequences of
CCoV-A76 are as follows—ORF1ab GenBank ID: AEQ61967.1; S
GenBank ID: AEQ61968.1; 3a GenBank ID: AEQ61969.1; 3c Gen-
Bank ID: AEQ61970.1; E GenBank ID: AEQ61971.1; M GenBank ID:
AEQ61972.1, N GenBank ID: AEQ61973.1; 7a GenBank ID: AEQ61974.
1; 7b GenBank ID: AEQ61975.1.
Phylogenetic and recombination analyses of CCoV-A76 spike
Phylogenetic trees were generated using the following
sequences from the NCBI GenBank database—CCoV-A76 GenBank
ID: AEQ61968.1; CCoV-1-71 GenBank ID: AY796289.1; CCoV-
Elmo/02 GenBank ID: AY307020.1; CCoV-CB/05 GenBank ID:
AAZ91437.1; CCoV-Giant-Panda GenBank ID: AY436637.1; FCoV-
WSU-79-1683 GenBank ID: X80799.1; FCoV-WSU-79-1146 Gen-
Bank ID: YP_004070194.1; FCoV-RM GenBank ID: ACT10854.1;
IBV-M41 GenBank ID: AAW33786.1; BCoV-Quebec GenBank ID:
AAL40400.1; Ferret-Enteric-CoV-MSU2 GenBank ID: ADD49358.1;
MHV-A59 GenBank ID: AAU06356.1; TGEV-Purdue GenBank
A.D. Regan et al. / Virology 430 (2012) 90–9998ID: ABG89335.1; HCoV-229E GenBank ID: AAG48592.1; SARS-
CoV GenBank ID: NP_828851.1; HCoV-NL63 GenBank ID:
AAS58177.1; HCoV-HKU1 GenBank ID: AAT98580.1; HCoV-OC43
GenBank ID: AAT84354.1.
Phylogenetic analysis and sequence alignments were per-
formed utilizing ClustalX 2.1 software. Phylogenetic trees were
generated using the Neighbor-Joining (NJ) clustering algorithm.
Bootstrap values were calculated from 2000 trees. Alignments
generated by ClustalX 2.1 were formatted using CLC Free Work-
bench 3 software. Analysis of CCoV-A76 S recombination events
was performed using the RDP 3 software with the BOOTSCAN/
RESCAN methodology (Heath et al., 2006; Martin et al., 2005).Acknowledgments
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